Toxic algae in some New Zealand freshwater ponds

Trials were conducted to test the ability of yohimbine, 4-aminopyridine and doxapram given by intravenous injection to antagonise xylazine sedation in red deer (Cervus elaphus). Yohimbine produced the best and most consistent result. The mean time taken for 34 animals to stand spontaneously after receiving yohimbine (0.2 to 0.25 mg/kg) was 2 minutes 25 seconds and this occurred, on average, 33 minutes after the initial doze of xylazine. Control deer took 67 and 104 minutes on average to stand after receiving intravenous (0.64–0.96 mg/kg) and intramuscular (1.0–1.5 mg/kg) injections of xylazine respectively. Two deer which received an overdose of xylazine (4 mg/kg) recovered 3 and 9 minutes respectively after receiving yohimbine. Two deer given a high intravenous dose of yohimbine (1.0 mg/kg) became mildly nervous and anxious, but returned to normal within an hour. 4-aminopyridine (0.3 mg/kg) alone produced some arousal from xylazine sedation (0.6–1.0 mg/kg) but was inconsistent. In combination with yohimbine (0.125 mg/kg) it produced rapid recovery in two deer but caused convulsions in two other deer.

Doxapram (1 mg/kg) produced respiratory stimulation and some arousal from xylazine sedation (0.6–1.0 mg/kg) in the majority of deer but the effect was transitory. Animals relapsed into moderate sedation and recumbency within 10 minutes and required vigorous stimulation to arouse them again.

Yohimbine, administered by intravenous injection at a dose rate of 0.2 to 0.25 mg/kg, appears to be a safe and reliable drug for the reversal of xylazine sedation in deer.     

Antagonism of xylazine sedation by 4-aminopyridine and yohimbine in cattle

Twenty-four crossbred steers (4 groups of 6 steers each) were injected IM with a standard dosage range of xylazine hydrochloride (0.2 to 0.3 mg/kg of body weight). When the steers were maximally sedated, group I (control group) were given isotonic saline solution (1 ml, IV), group II were given 4-aminopyridine (4-AP, 0.3 mg/kg) IV, group III were given yohimbine hydrochloride (0.125 mg/kg) IV, and group IV were given 4-AP (0.3 mg/kg) plus yohimbine hydrochloride (0.125 mg/kg) IV. The 4-AP decreased mean standing time (MST; time until animal could stand unaided) from 94.3 minutes (control) to 13.4 minutes. Yohimbine decreased MST to 27 minutes. The combination of 4-AP + yohimbine decreased MST to 7.4 minutes. Mean total recovery time (MTRT; time from xylazine injection until normal behavior, including eating and drinking) was not significantly (P = greater than 0.05) decreased from control values by any of the antagonists tested. The combination of 4-AP + yohimbine decreased MST in animals given a 3X overdose of xylazine (0.6 mg/kg) from 124 minutes (control) to 30.3 min. The MTRT was not significantly (P greater than 0.05) decreased from control values. Two animals given a 5X overdose of xylazine (1 mg/kg) and then given 4-AP + yohimbine had a MST of 32.5 minutes and a MTRT of 3.7 hours. The combination of 4-AP + yohimbine produced marked antagonism of xylazine sedation in cattle. The combination of antagonists may prove to be useful for the arousal of animals sedated with xylazine alone or with a combination of sedatives including xylazine.     

Effect of yohimbine on xylazine-induced immobilization in white-tailed deer

Two groups of white-tailed deer were given IM injections of xylazine with a projectile syringe. Deer in one of the groups served as controls and did not receive any treatments other than xylazine. Deer in the other group were given yohimbine IV at various times (15 to 171 minutes) to evaluate its effect on xylazine-induced immobilization. In 5 control deer given 3.7 +/- 1.2 mg of xylazine/kg (mean +/- SD), onset of recumbency was 13 +/- 2 minutes and time to standing was 268 +/- 76 minutes. In 20 principal deer given 2.8 +/- 1.0 mg of xylazine/kg, onset of recumbency was 8 +/- 7 minutes, time to sitting after giving yohimbine was 3 +/- 4 minutes in 18 of the deer, and time to standing after giving yohimbine was 4 +/- 5 minutes in 19 of the deer. Most of these deer were still moderately sedated 30 minutes after injection of yohimbine, but none of them became reimmobilized or as deeply sedated as before the injection of yohimbine. Yohimbine also reversed the bradycardia and respiratory depression induced by xylazine.     

Reversal of pentobarbital anesthesia with 4-aminopyridine and yohimbine in cats pretreated with acepromazine and xylazine

In 2 separate experiments, groups of atropinized cats (6 cats/group) were given acepromazine (0.25 mg/kg of body weight) or xylazine (2.2 mg/kg) IM and anesthetized with pentobarbital. The mean dose of pentobarbital was decreased approximately 36% by acepromazine, and approximately 80% by xylazine, compared with published doses. Anesthetized cats were given IV saline solution (control groups) or were given the antagonists 4-aminopyridine (4-AP; 0.5 mg/kg), yohimbine (0.4 mg/kg), or 4-AP + yohimbine (0.5 mg/kg and 0.4 mg/kg, respectively). In acepromazine-treated cats, 4-AP + yohimbine was the most effective antagonist; arousal and walking occurred in an average of 10.4 minutes and 91.7 minutes, respectively. Yohimbine enhanced the antagonistic effects of 4-AP. In xylazine-treated cats, yohimbine was an effective antagonist; arousal and walking occurred in an average of 2.8 minutes and 12.8 minutes, respectively. Yohimbine did not enhance the antagonistic effects of 4-AP. Mean respiratory rates were decreased by acepromazine, but were increased by xylazine. Thus, respiratory rate depression by pentobarbital was not as marked with xylazine as it was with acepromazine. Changes in mean heart rate were not remarkable with either sedative, and cardiac irregularities were not palpated or auscultated. In healthy cats, the duration of pentobarbital anesthesia can be controlled by 4-AP + yohimbine (acepromazine-pretreated cats) or by yohimbine alone (xylazine-pretreated cats).     

The reversal of xylazine hydrochloride by yohimbine and 4-aminopyridine in goats

Yohimbine, 4-aminopyridine, and a combination of the 2 drugs were studied to assess their potential as antagonists to xylazine in goats. Twenty-four small East African goats were divided randomly into 4 groups of 6 goats each in a placebo-controlled study. They were all treated with intramuscular xylazine at 0.44 mg/kg. At the time of maximum sedation, sterile water was administered intravenously to the control group, 0.15% 4-aminopyridine at 0.4mg/kg to Group 2, 0.1% yohimbine at 0.25 mg/kg to Group 3, and the combination of the 2 drugs at the same dose rates to Group 4. The yohimbine/4-aminopyridine combination was also used to antagonise xylazine at 0.88mg/kg in 6 goats. The heart rate, respiratory rate and rate of ruminal movements, the pedal and palpebral reflexes as well as the reaction to noxious stimuli, the standing time and the total recovery time were established and evaluated to assess the effects of the treatments. The drugs reversed the xylazine-induced decrease in the heart rate, respiratory rate and rate of ruminal movements, and also rapidly restored the reflexes as well as the reaction to noxious stimulation. In addition, they significantly (P < 0.05) decreased the mean standing time. The mean total recovery time was decreased significantly (P < 0.05) by 4-aminopyridine and the yohimbine/4-aminopyridine combination, but non-significantly (P > 0.05) by yohimbine. No relapse in sedation occurred. Overall, the combination of yohimbine and 4-aminopyridine produced better responses than the individual drugs, and may therefore be used for rapid reversal of xylazine-induced sedation in goats. Yohimbine or 4-aminopyridine may also be useful for this purpose but recovery may be prolonged.     

The antagonism of ketamine/xylazine anesthesia ("Hellabrunn mixture") in wild zoo ruminants

The ability of the antagonists tolazoline, yohimbine and the combination of yohimbine with 4-aminopyridine to reverse the effects of the xylazine-component of the "Hellabrunn mixture" (125 mg/ml xylazine and 100 mg/ml ketamine) on nondomestic zoo ruminants is discussed. Arousal time, recovery time and changes in the parameter of circulatory and respiratory functions after antagonization are shown. Tolazoline is able to antagonize the xylazine effect completely within a short time. Using a dosage of 3-5 mg/kg there is a marked negative effect on the cardio-vascular system. Yohimbine in the used dosage of 0.25-0.3 mg/kg in non-domestic ruminants did not approve in its effects. Combining yohimbine (0.25-0.3 mg) with 4-aminopyridine (0.5 mg/kg) recovery time is about 30 minutes. The negative effect on the cardio-vascular system is less pronounced compared with tolazoline.     

Use of yohimbine and 4-aminopyridine to antagonize xylazine-induced immobilization in North American Cervidae

Four captive moose (Alces alces), 4 mule deer (Odocoileus hemionus), and 5 white-tailed deer (Odocoileus virginianus) were immobilized with xylazine (0.63 to 1.29 mg/kg of body weight, IM). Mean induction times for the moose were 17 minutes and for the deer, 14 and 10 minutes, respectively. According to published data and past experience, the dosage of xylazine used would be expected to provide 115, 120, and 100 minutes of immobilization in captive moose, mule deer, and white-tailed deer, respectively. In the present study, maximal sedation of the moose and deer was reversed with successive injections (given IV) of yohimbine (0.15 mg/kg) and 4-aminopyridine (0.26 to 0.29 mg/kg). These produced sternal recumbency-to-arousal intervals of 1 to 15 minutes and recumbency-to-standing or walking intervals of 1 to 24 minutes. Relapses to recumbency were not observed. The injections of the reversal drugs produced marked increases in respiratory rate and heart in the moose and deer, without occurrence of muscle tremors or convulsions. The administrations of yohimbine and 4-aminopyridine markedly enhanced the speed of recovery from xylazine-induced immobilization in moose and deer.     

Antagonism of xylazine sedation with yohimbine, 4-aminopyridine, and doxapram in dogs

Groups of atropinized dogs (6 dogs/group) were sedated with xylazine (2.2 mg/kg of body weight, IM). At recumbency, the dogs were given IV saline solution (control groups), yohimbine (0.05, 0.1, and 0.2 mg/kg), 4-aminopyridine (4-AP; 0.3, 0.6, and 0.9 mg/kg), doxapram (0.5, 1.0, 2.0, and 4.0 mg/kg), or the smallest dose of these antagonists in dual combinations or in triple combination. Two additional groups were sedated with an overdose of xylazine (11 mg/kg, IM). At recumbency, 1 of these groups was given saline solution IV and the other group was given yohimbine IV (0.4 mg/kg) as the antagonist. With the 2.2 mg/kg dose of xylazine, control mean arousal time (MAT) and mean walk time (MWT) were 15.5 minutes and 24.8 minutes, respectively. These values were decreased by the individual antagonists to 0.5 to 2.5 minutes and 0.9 to 7.4 minutes, respectively. Approximate equipotent doses of antagonists (mg/kg) were: yohimbine, 0.2; 4-AP, 0.6; and doxapram, 0.5. Relapses did not occur after yohimbine or 4-AP. With doxapram, muscle tremors and spasms, abnormal postures, or aggressive behavior occurred in several dogs and several dogs had partial or complete relapses. The small doses of individual antagonists were synergistic with regard to MAT, MWT, and duration of residual sedation, but the various combinations of antagonists were not more effective in these regards than were larger doses of the single antagonists. With the overdose of xylazine, control MAT and MWT were 41.5 minutes and 144.5 minutes, respectively. Yohimbine decreased these values to 2.2 minutes and 2.5 minutes, respectively. Relapses did not occur.(ABSTRACT TRUNCATED AT 250 WORDS)     

Reversal of xylazine-induced sedation in llamas, using doxapram or 4-aminopyridine and yohimbine

For each of 3 separate evaluations, 6 fasted llamas (Lama glama) were sedated with xylazine (1.1 mg/kg of body weight, IV) and then 15 minutes later were given normal saline solution (5.0 ml, IV; control values), doxapram (2.2 mg/kg, IV), or 4-amino-pyridine (0.3 mg/kg, IV) and yohimbine (0.125 mg/kg, IV). After administration of 4-aminopyridine and yohimbine, the llamas stood in a mean of 11 minutes and resumed eating in a mean of 34 minutes; both means were significantly less (P less than 0.05) than control values (46 minutes and 67 minutes, respectively). Doxapram induced muscle fasciculations, and (compared with control values) did not significantly decrease the time to standing (41 minutes) or the time until the animals resumed eating (68 minutes). Yohimbine and 4-aminopyridine in combination rapidly antagonized xylazine-induced sedation in llamas, whereas doxapram was ineffective as an antagonist of xylazine-induced sedation.     

Antagonism of xylazine sedation in steers by doxapram and 4-aminopyridine

Five groups of 6 fasted crossbred steers were injected IM with standard dosages of xylazine hydrochloride (0.3 to 0.5 mg/kg). At maximal sedation, the steers were injected IV with the antagonists' doxapram (1.0 mg/kg), doxapram + yohimbine (0.125 mg of yohimbine/kg), doxapram + 4-aminopyridine (4-AP; 0.3 mg of 4-AP/kg), or 4-AP + yohimbine. One group was given 1.0 ml of saline solution IV instead of antagonists. Doxapram, doxapram + yohimbine, doxapram + 4-AP, and 4-AP + yohimbine decreased mean standing time (time from antagonist injection until animal could stand unaided) to 17.0, 4.3, 3.3, and 4.5 minutes, respectively--significantly (P less than 0.05) down from a control value of 49.8 minutes. Mean total recovery time (time from xylazine injection until animal resumed eating) was decreased to 78 minutes by doxapram and 81.6 minutes by doxapram + 4-AP--significantly (P less than 0.05) down from the control value of 142.9 minutes. Respiratory character was improved (depth of respiration was increased) only by doxapram + 4-AP. Relapses to recumbency and marked sedation were not seen in steers given doxapram + 4-AP or the saline solution. One steer given doxapram, 2 given doxapram + yohimbine, and 1 given 4-AP + yohimbine relapsed to recumbency and sedation. Recovery was relatively smooth in steers given doxapram + 4-AP or 4-AP + yohimbine. Animals given doxapram or doxapram + yohimbine had difficult recoveries.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of Three Midazolam-Xylazine Mixtures Preliminary Trials in Dogs

The depressant effects of midazolam and xylazine on the central nervous system (CNS) were evaluated in 12 dogs. Xylazine was administered to six dogs (1.1 mg/kg intravenously [IV]) followed in 5 minutes by midazolam (1.0 mg/kg intramuscularly [IM]). In a second group of six dogs, xylazine (2.2 mg/kg IM) was followed in 5 minutes by midazolam (1.0 mg/kg IV). Both drug regimens induced rapid and profound sedation or anesthesia. Duration of action varied with the doses and routes of administration. Dogs given the high dose of xylazine IM had an arousal time of 95.4 +/- 8.9 minutes and a walking time of 155.4 +/- 8.8 minutes. These values exceeded the IV xylazine values threefold. Partial reversal of CNS depression was accomplished with either a benzodiazepine antagonist (flumazenil) or an alpha-2 antagonist (yohimbine). In a separate trial, a mixture of xylazine (0.55 mg/kg), midazolam (1.0 mg/kg), and butorphanol (0.1 mg/kg) with and without glycopyrrolate was evaluated in eight dogs. As with the xylazine-midazolam combinations, the CNS depressant effect of this mixture was clinically indistinguishable from anesthesia achieved with other rapid-acting injectable agents. Clinical signs of CNS depression were readily and completely antagonized by the simultaneous injection of flumazenil and yohimbine.     

Influence of yohimbine on xylazine-induced depression of central nervous, gastrointestinal and cardiovascular function in the calf

The antagonistic effect of yohimbine HCl (0.25 mg/kg IV), and alpha 2-adrenergic antagonist, on xylazine (0.05 mg/kg IV)-induced depression of central nervous and cardiovascular activity and rumen motility was studied in post-weaning calves. Yohimbine, administered 3 min post-xylazine, significantly decreased the duration of rumen amotility (38.3 +/- 4.2 min versus 14.0 +/- 2.2 min). Sedation, however, as monitored by the duration of fetlock knuckling in calves suspended in a body sling, was not shortened by yohimbine treatment. Yohimbine alone produced a significant tachycardia and led to a reduction of the duration of xylazine-induced bradycardia. Our data indicate that yohimbine produces a significant reversal of xylazine-induced rumen hypomotility at dosage levels that are without effect on sedation induced by this drug.     

The reversal of xylazine/ketamine immobilisation of fallow deer with yohimbine

Fallow deer were immobilised using a combination of xylazine and ketamine. Adult males (n = 10) and adult females (n = 10) received 4 mg/kg of each drug intramuscularly. Juveniles (n = 11) received 2 mg/kg of each drug, intravenously. Times to recumbency were as follows: adult males 4.9 +/- 2.9 min, adult females 4.1 +/- 1.9 min, juveniles 2.3 +/- 1.1 min. After 30 min each deer received 0.2 mg/kg of yohimbine, or an equal volume of sterile diluent intravenously. Yohimbine substantially reduced the recovery times of treated deer. Adults males were releasable 7.2 +/- 4.3 min after yohimbine administration, whereas control males were not releasable until 165 +/- 18 min. Treated adult females were releasable after 6.6 +/- 4.3 min, while control females were not releasable until 84 +/- 29 min. Juveniles were releasable 2.1 +/- 0.8 min after administration of yohimbine but control juveniles were not releasable until 62 +/- 16 min. Xylazine/ketamine administration produced statistically significant changes in packed cell volume, total plasma protein, albumin, sodium, glucose, creatine phosphokinase and inorganic phosphate values after 30 min. Yohimbine administration had no effect on these changes.     

Xylazine and a xylazine/fentanyl citrate/azaperone combination in farmed deer. II: velvet antler removal and reversal combinations

Three studies were undertaken on farmed red and red x wapiti deer to evaluate xylazine and a xylazine/fentanyl citrate/azaperone combination for velvet antler removal. In the first experiment, 30 1-2 year-old red and 25% red x wapiti deer whose velvet was to be removed were given either 5% xylazine alone at 0.5 mg/kg body weight intramuscularly or the same dose rate of a commercially available mixture of 5% xylazine with the addition of 0.4 mg of fentanyl citrate and 3.2 mg of azaperone per ml. Physiological, behavioural and analgesic responses and reversal times after yohimbine or yohimbine and naloxone were monitored. There were no differences in heart rate, respiration rate, sedative or analgesic properties detected between xylazine or the xylazine/fentanyl citrate/azaperone combination. All deer became recumbent, but those given the xylazine/fentanyl citrate/azaperone combination became recumbent more rapidly than those given xylazine alone (9.4 and 12.5 minutes, respectively, p<0.05). The arousal pattern and timing of reversal of xylazine and xylazine/fentanyl citrate/azaperone using yohimbine and yohimbine and naloxone, respectively, were similar. The second experiment evaluated the reversal of the xylazine/fentanyl citrate/azaperone combination with either yohimbine or yohimbine and naloxone in 43 3-year-old red deer stags after velvet antler removal. There were no differences in arousal pattern or time to standing between reversal treatments. Sixteen 1-year-old red and 25% red x wapiti stags were used in the third experiment to evaluate clinically the analgesic properties of xylazine and xylazine/fentanyl citrate/azaperone combination during velvet removal without the application of a local anaesthetic agent. Withdrawal responses were observed in most deer after the xylazine/fentanyl citrate/azaperone combination at dosages containing 0.5, 0.7 and 0.75 mg of xylazine/kg and after xylazine alone at 0.7 mg/kg, indicating that insufficient analgesia was provided by the systemic agent for the surgical procedure of velvet antler removal. These studies have shown that the knock-down effect of the xylazine/fentanyl citrate/azaperone combination was more rapid than that of xylazine alone, but that other physiological, behavioural and analgesic responses at doses used and evaluated by the methods used were similar. Reversal of both the xylazine and xylazine/fentanyl citrate/azaperone combination was similar when using either yohimbine alone for xylazine and the xylazine/fentanyl citrate/azaperone combination or yohimbine and naloxone for the xylazine/fentanyl citrate/azaperone combination. The evaluation of surgical analgesia for antler removal suggested that both xylazine alone and the xylazine/fentanyl citrate/azaperone combination provided insufficient analgesia and that local anaesthetic should be used in all cases.     

Prompt arousal from fentanyl-droperidol-pentobarbital anesthesia in dogs: a preliminary study.

Groups of fentanyl-droperidol-pentobarbital-anesthetized dogs (n = 6 dogs/group) were given IV saline solution (control group), graded doses of naloxone (0.01, 0.1, 1.0, 10.0 mg/kg) or fixed doses of 4-aminopyridine (0.5 mg/kg), yohimbine (0.4 mg/kg), or doxapram (5.0 mg/kg) alone or in combination with a fixed dose of naloxone (1.0 mg/kg). The purpose was to determine which drug or drug combination would produce arousal most quickly without producing obvious undesirable side effects. Control group mean arousal time, mean walk time and mean duration of postarousal sedation were 66.1 minutes, 112.4 minutes and 5.6 hours, respectively. Naloxone (1.0 mg/kg) decreased mean arousal time to 10.8 minutes without significantly decreasing mean walk time or mean duration of postarousal sedation. The combination of naloxone + doxapram decreased mean arousal time and mean walk time to 1.0 minute and 57.1 minutes, respectively, without decreasing mean duration of postarousal sedation. In all groups, emergence from anesthesia was smooth. Relapses or undesirable side effects were not observed. Naloxone + doxapram is superior to naloxone alone for arousal of fentanyl-droperidol-pentobarbital-anesthetized dogs.     

Effect of yohimbine on xylazine-ketamine anesthesia in cats

Xylazine and ketamine are an anesthetic combination used in feline practice for routine surgical procedures. In a controlled study, we evaluated the effects of yohimbine, an antagonist of xylazine, on the anesthesia induced by this anesthetic combination in cats. Two intramuscular doses of xylazine and ketamine (2.2 mg of xylazine/kg plus 6.6 mg of ketamine/kg and 4.4 mg of xylazine/kg plus 6.6 mg of ketamine/kg) caused approximately 60 and 100 minutes of anesthesia, respectively, in control cats. When yohimbine (0.1 mg/kg) was given intravenously 45 minutes after ketamine administration, the cats regained consciousness within 3 minutes. They were ambulatory 1 to 2 minutes after regaining consciousness. Yohimbine also reversed the bradycardia and respiratory depression elicited by xylazine-ketamine. The results indicated that yohimbine may be useful for controlling the duration of xylazine-ketamine anesthesia in cats.     

Reversal of thiopental-induced anesthesia by 4-aminopyridine, yohimbine, and doxapram in dogs pretreated with xylazine or acepromazine

Groups of atropinized dogs (6 dogs/group) were sedated, using xylazine HCl (2.2 mg/kg of body weight, IM) or acepromazine maleate (0.25 mg/kg, IM), and were anesthetized to loss of pedal reflexes, using thiopental, IV. The dogs were given 1 of the following test antagonists, IV: saline solution (2 ml; control group), 4-aminopyridine (4-AP; 0.5 mg/kg), yohimbine (0.4 mg/kg), doxapram (5.0 mg/kg), or dual combinations of the latter 3 substances in the same doses as used for each agent. In xylazine-treated dogs, the mean dosage of thiopental required to induce anesthesia was 4.8 mg/kg. Control mean arousal time (MAT) and walk time (MWT) were 37.1 minutes and 53.8 minutes, respectively. These values were decreased to less than 2 minutes and less than 3 minutes, respectively, by yohimbine, 4-AP + yohimbine, and doxapram + yohimbine. With doxapram and with 4-AP + doxapram, MAT was less than 2 minutes and MWT was less than 8 minutes. In acepromazine-treated dogs, the mean dosage of thiopental required for anesthesia was 15.0 mg/kg. Control MAT and MWT were 20.7 minutes and 36.5 minutes, respectively. These values were decreased to 8.1 minutes and 18.1 minutes, respectively, by doxapram, and to 3.5 minutes and 19.9 minutes, respectively, by doxapram + yohimbine. Doxapram, 4-AP + doxapram, and doxapram + yohimbine caused periodic extensor rigidity before and during arousal. This rigidity was accompanied by opisthotonos in 2 dogs of the doxapram + yohimbine group and may have been mild tonic seizures.(ABSTRACT TRUNCATED AT 250 WORDS)     

Medetomidine, a new sedative-analgesic for use in the dog and its reversal with atipamezole

The sedative and physiological effects of intramuscular medetomidine (20 and 40 μg/kg) in dogs were compared with those of xylazine (2 mg/kg). The efficacy of atipamezole (200 μg/kg), as an antagonist given 15 or 45 minutes after medetomidine (40 μg/kg) was studied. Following medetomidine, onset of sedation was rapid, and depth and duration of sedation were dose dependent. The higher dose produced jaw relaxation, depression of the pedal reflex, downward rotation of the eye and dogs could be positioned for radiography of the hips. Side effects were similar after either medetomidine or xylazine, and included bradycardia, a fall in respiratory rate and muscle tremor. Vomiting during induction was less frequent after medetomidine than after xylazine. Intramuscular administration of atipamezole rapidly reversed the sedative effects of medetomidine. Signs of arousal were seen within three minutes; all dogs could stand within 10 minutes and appeared clinically normal. Heart and respiratory rates rose, but did not return to presedation values. Relapse to sedation was not noted.     

Cardiopulmonary effects of xylazine and yohimbine in laterally recumbent sheep.

The effects of yohimbine (0.125 mg/kg) on cardiopulmonary parameters in six adult, xylazine treated (0.15 mg/kg), laterally recumbent sheep were studied. Following collection of baseline data, xylazine was administered intravenously and data were collected five and fifteen minutes later. At twenty minutes post-xylazine either yohimbine (0.125 mg/kg) or saline was given and further collection of data occurred at 25, 30, 40 and 50 minutes. Xylazine administration resulted in significant (P less than 0.05) respiratory depression, as reflected by a decrease in arterial oxygen partial pressure (PaO2). No significant changes in haemodynamic variables were observed. Yohimbine produced a significant improvement in PaO2 at the 50 minute period and abolished the paradoxical respiratory pattern when present. The results indicated that yohimbine can be used as an antagonist to control the duration of xylazine induced respiratory depression, although the degree of reversal was less than is clinically desirable.     

Effect of xylazine on heart rate and arterial blood pressure in conscious dogs, as influenced by atropine, 4-aminopyridine, doxapram, and yohimbine

The effects of xylazine on heart rate (HR) and mean arterial blood pressure (ABP) were studied in 5 conscious male dogs. An IV injection of xylazine (1 mg/kg) caused a decrease in HR, which was accompanied by sinus arrhythmia. Xylazine administration also caused an initial increase in ABP, which was followed by a decrease. Atropine sulfate (0.045 mg/kg, IM) increased both the ABP and HR, but prevented xylazine-induced bradycardia only in 3 of 5 dogs. The other 2 dogs had to be given a supplemental dose of atropine sulfate (0.01 mg/kg, IV) before xylazine-induced bradycardia was antagonized. In addition, atropine sulfate potentiated xylazine-induced hypertension for 60 minutes. Yohimbine, an alpha 2-adrenoreceptor blocking agent, given IV at a dosage of 0.1 mg/kg, antagonized hypertension, hypotension, and bradycardia induced by xylazine. In addition, doxapram HCl, given IV at a dosage of 5.5 mg/kg, antagonized bradycardia but potentiated xylazine-induced hypertension, and an IV injection of 4-aminopyridine at a dosage of 0.5 mg/kg did not affect the cardiovascular actions of xylazine. It was concluded that atropine sulfate at the IM dosage of 0.045 mg/kg may be insufficient to antagonize xylazine-induced bradycardia but may potentiate xylazine-induced hypertension, and yohimbine may be useful in antagonizing these untoward reactions associated with xylazine administration. Doxapram and 4-aminopyridine were not found to be beneficial.